Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00314873
Recruitment Status :
First Posted : April 17, 2006
Last Update Posted : June 3, 2014
Indiana University School of Medicine
Information provided by (Responsible Party):
Indiana University ( Indiana University School of Medicine )
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Condition or disease
Drug: Gleevec (imatinib)
Thymic carcinomas are particularly more concerning due to their aggressive metastatic nature and shorter overall survival, in comparison to their lesser-malignant thymoma counterparts. This necessitates the need for systemic therapy. Due to the paucity of thymic carcinoma cases, the ideal regimen for locally advanced or metastatic thymic carcinomas is not defined.To this point, there has not been a study using imatinib in thymic tumors expressing the KIT tyrosine kinase protein or PDGF tyrosine kinase protein. This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histological or cytological proof of advanced C-KIT positive or PDGFR positive thymic carcinoma. For protocol purposes, advanced disease is defined as disease
Patient must have at least one documented measurable lesion obtained by imaging within 28 days prior to being registered for protocol therapy.
No prior imatinib therapy.
Age > 18 years at the time of consent
ECOG performance status of 0 or 1
ANC ≥ 1500/mm3,Platelet count ≥ 100,000/mm,Total bilirubin < 1.5ULN,3.10 Serum creatinine ≤ 1.7 mg/dl,ALT and AST ≤ 3 x ULN
Clinically significant infections as judged by the treating investigator
Clinically significant concurrent illnesses
Females of childbearing potential not using birth control or breastfeeding
Prior radiation therapy > 25% of the bone marrow
Symptomatic brain metastasis
History of Grade III/IV cardiac problems
History of major surgery within 14 days prior to being registered
Treatment with any investigational agent within 30 days prior to being registered for protocol therapy.